BlackRock, Inc. filed an amended beneficial ownership statement with the SEC on October 27, 2026, disclosing a 7.2% stake in First Tracks Biotherapeutics Inc. as of September 30, 2026.

Key Highlights

  • Aggregate beneficial ownership: BlackRock reported 2,558,473 shares of First Tracks Biotherapeutics Inc. common stock beneficially owned.
  • Percent of class: The 2,558,473 shares represent 7.2% of the outstanding common stock of First Tracks Biotherapeutics Inc.
  • Sole voting power: BlackRock reported sole voting power over 2,499,954 shares, with zero shared voting power.
  • Sole dispositive power: BlackRock reported sole dispositive power over all 2,558,473 shares, with zero shared dispositive power.
  • Date of event: The event requiring this filing occurred on September 30, 2026.
  • Ordinary course certification: BlackRock certified the shares "were acquired and are held in the ordinary course of business and were not acquired and are not held for the purpose of or with the effect of changing or influencing the control of the issuer."

BlackRock's Amended Position in First Tracks Biotherapeutics

BlackRock, Inc. (NYSE:BLK), a Delaware-incorporated holding company headquartered at 50 Hudson Yards, New York, NY 10001, filed an amendment (Amendment No. 1) to its Schedule 13G disclosing beneficial ownership of shares in First Tracks Biotherapeutics Inc., a biotherapeutics company whose principal executive offices are located at 10770 Wateridge Circle, Suite 210, San Diego, CA 92121. The filing was signed by Spencer Fleming, Managing Director, on October 27, 2026, and covers a reporting event date of September 30, 2026.

According to the filing, the disclosure reflects securities beneficially owned, or deemed to be beneficially owned, by certain business units of BlackRock, Inc. and its subsidiaries and affiliates, referred to in the filing as the "Reporting Business Units." The filing states it does not include securities, if any, beneficially owned by other business units whose beneficial ownership is disaggregated from that of the Reporting Business Units in accordance with SEC Release No. 34-39538 (January 12, 1998). The relevant subsidiary information is provided in Exhibit 99 attached to the filing.

The filing further discloses that "various persons have the right to receive or the power to direct the receipt of dividends from, or the proceeds from the sale of the common stock of First Tracks Biotherapeutics Inc.," and that no single person's interest exceeds five percent of the total outstanding common shares. BlackRock is classified as a parent holding company (type "HC") in this filing. The CUSIP number for First Tracks Biotherapeutics Inc. common stock is 337185102.

What Was Disclosed

BlackRock, Inc. disclosed an amended beneficial ownership position of 2,558,473 shares, equal to 7.2% of First Tracks Biotherapeutics Inc. common stock, as of September 30, 2026, with sole dispositive power over all reported shares and sole voting power over 2,499,954 shares.